Cellzome reports that its research collaboration with Novartis has been extended until June 2008. Cellzome will continue to apply its technology to identify tractable therapeutic and pharmacological targets, as well as potential off-target effects of active Novartis compounds.
The work is being conducted between Cellzome's Heidelberg operations and Novartis' Developmental and Molecular Pathways group based in Cambridge, MA. Novartis has made an equity investment in Cellzome and contributes research funding. There are also lead compound development options for both companies in exchange for licenses, milestone payments, and royalties.
In 2004, Cellzome and Novartis entered into a collaboration to chart the physical and functional protein maps of key cellular pathways of a variety of diseases with the potential to select the best protein targets within these pathways for the development of new drug candidates.